Arrowhead Pharmaceuticals (ARWR) H.C. Wainwright 28th Annual Global Investment Conference summary
Event summary combining transcript, slides, and related documents.
H.C. Wainwright 28th Annual Global Investment Conference summary
16 Sep, 2026Platform and pipeline overview
Developed a broad RNAi platform targeting multiple cell types, with five represented in clinical candidates.
Transitioned to a commercial stage with 21–22 drug candidates in clinical studies.
Plans to access a new cell type every 18–24 months, expanding beyond liver to CNS and other tissues.
Focused on building a broad-based company addressing diverse indications.
REDEMPLO (plozasiran) launch and expansion
REDEMPLO approved for FCS, targeting both genetic and clinically defined FCS populations.
Contracting with payers established; sales force expanded to address larger clinical FCS population.
Preparing for SHTG launch in Q2 2027, with further sales force growth planned in early 2027.
SHASTA-3 and SHASTA-4 trial results
Achieved ~80% reduction in triglycerides in severe hypertriglyceridemia patients.
Statistically significant reduction in acute pancreatitis risk, with 78–100% risk reduction in high-risk subgroups.
Clean safety profile: no significant liver, hypersensitivity, or thrombocytopenia issues; no increase in liver fat.
Latest events from Arrowhead Pharmaceuticals
- REDEMPLO sHTG review and multiple 2027 pipeline milestones anchor the outlook.ARWR
Jefferies Global Healthcare Conference - REDEMPLO’s launch growth and SHTG preparations led a year of major pipeline advances.ARWR
Q4 2026 - ARO-MAPT cut CSF tau by up to 73% at Day 105, supporting quarterly-or-less-frequent dosing.ARWR
Study update - Breakthrough dual gene knockdown, robust triglyceride therapy, and pipeline innovation drive growth.ARWR
Morgan Stanley 24th Annual Global Healthcare Conference - Strong efficacy, safety, and launch readiness position plozasiran for high-impact SHTG entry.ARWR
12th Annual Cantor Fitzgerald Global Healthcare Conference - Plozasiran delivers robust, sustained efficacy and safety for high-risk SHTG patients.ARWR
KOL event - SHASTA-3/4 trials drove strong efficacy, revenue growth, and global REDEMPLO expansion.ARWR
Q3 2026 - Plozasiran nears launch after robust phase III data, with lung program readouts expected soon.ARWR
Chardan's 8th Annual Genetic Medicines Conference - Q2 FY2025 saw $542.7M revenue, $370.4M net income, and funding secured into 2028.ARWR
Q2 2025